IRADIMED insider Roger E. Susi files Form 4 for plan sales

Rhea-AI Filing Summary

IRADIMED (IRMD) insider activity: CEO/President/Chairman and 10% owner Roger E. Susi filed a Form 4 reporting open‑market sales on 10/27/2025 pursuant to a Rule 10b5‑1 trading plan adopted on June 16, 2025.

The filing shows three sales by an indirect holder: 4,242 shares at a weighted average price of $77.56, 700 shares at $78.33, and 58 shares at $79.12. Following these transactions, 2,327,500 shares were beneficially owned indirectly by the Phillip Susi 2008 Dynasty Trust. Additional indirect holdings listed include 162,950 shares by the Roger E. Susi Revocable Trust and 2,062,500 shares by the Matthew Susi 2008 Dynasty Trust, with a stated disclaimer of beneficial ownership except to the extent of pecuniary interest.

Insights

Insider trading and governance analyst

Routine 10b5‑1 plan sales; neutral governance signal.

Roger E. Susi reported sales executed on 10/27/2025 under a pre‑established Rule 10b5‑1 plan. Trades were completed in multiple executions at weighted average prices of $77.56, $78.33, and $79.12, consistent with standard programmatic selling.

The filing lists post‑trade indirect holdings of 2,327,500 shares via the Phillip Susi 2008 Dynasty Trust, plus other indirect positions, alongside a disclaimer of beneficial ownership where applicable. This is informational; actual market impact depends on holder decisions and trading volumes.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Susi Roger E.

(Last) (First) (Middle)

C/O IRADIMED CORPORATION

12705 INGENUITY DRIVE

(Street)

ORLANDO FL 32826

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
IRADIMED CORP [ IRMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
	CEO, PRESIDENT, CHAIRMAN

3. Date of Earliest Transaction (Month/Day/Year)
10/27/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/27/2025		S(1)		4,242	D	$77.56(2)	2,328,258	I	By Phillip Susi 2008 Dynasty Trust
Common Stock	10/27/2025		S(1)		700	D	$78.33(3)	2,327,558	I	By Phillip Susi 2008 Dynasty Trust
Common Stock	10/27/2025		S(1)		58	D	$79.12(4)	2,327,500	I	By Phillip Susi 2008 Dynasty Trust
Common Stock								162,950	I	By Roger E. Susi Revocable Trust
Common Stock								2,062,500(5)	I	By Matthew Susi 2008 Dynasty Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 16, 2025.

2. This transaction was executed in multiple trades at prices ranging from $76.99 to $77.98. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

3. This transaction was executed in multiple trades at prices ranging from $78.00 to $78.96. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

4. This transaction was executed in multiple trades at prices ranging from $79.07 to $79.16. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

5. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all the reported shares for purposes of Section 16 or for any other purpose.

	/s/ Roger E. Susi	10/27/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did IRMD’s CEO report on Form 4?

Roger E. Susi reported insider sales executed on 10/27/2025 under a Rule 10b5-1 trading plan adopted on June 16, 2025.

How many IRMD shares were sold and at what prices?

Sales were 4,242 shares at a weighted average of $77.56, 700 shares at $78.33, and 58 shares at $79.12.

What are the reported post-transaction holdings?

Indirect holdings include 2,327,500 shares by the Phillip Susi 2008 Dynasty Trust, and 162,950 shares by the Roger E. Susi Revocable Trust.

Is there a beneficial ownership disclaimer?

Yes. The reporting person disclaims beneficial ownership of certain securities except to the extent of his pecuniary interest.

What is Roger E. Susi’s role at IRMD?

He is CEO, President, Chairman, and a 10% Owner of IRADIMED Corporation.

Were the sales executed in multiple trades?

Yes. Each reported transaction was executed in multiple trades within the stated price ranges, with weighted average prices disclosed.